Concentra Group Holdings Parent, Inc.(CON)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Concentra Group Holdings Parent, Inc. (CON) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CON at 64.3/100 on a 32-signal composite quality model, placing it at rank #559 of 2,962 stocks — the top 25% of the AI-ranked universe. CON scores in the top quartile across earnings quality (78.9), balance sheet strength (76.6). Based on the latest XBRL financial filings (Q2 2026), Concentra Group Holdings Parent, Inc. reports quarterly revenue of $606.0M, net income of $65.3M, an operating margin of 19.0%. Top institutional holders of CON by reported 13-F value include BlackRock, PRICE T ROWE ASSOCIATES, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. CON trades on the NYSE exchange and files with the SEC under CIK 2014596. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Concentra Group Holdings Parent, Inc. directly from SEC EDGAR.
AI Quality Score
64.3/100
AI Rank
#559
Revenue
$606.0M
Net Income
$65.3M
Free Cash Flow
$119.5M
Operating Margin
19.0%
CON key financials by period
Concentra Group Holdings Parent, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$2.2B
$166.4M
15.4%
FY 2024
10-K
$1.9B
$166.5M
16.0%
FY 2023
10-K
$1.8B
$179.9M
15.7%
FY 2022
10-K
$1.7B
$166.7M
15.0%
Institutions holding CON
Institutional investors reporting a position in Concentra Group Holdings Parent, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue grew 10.0% YoY to $606.0M in Q2 FY2026, with operating margin expanding to 19.0% from 16.3% as cost of services fell to 68.3% of revenue.
Biggest Revenue Drivers
Occupational health centers$553.5M
91% of revenue; driven by organic increases in patient visit volume and revenue per visit
Onsite health clinics$38.8Mvs $22.6M prior year
Growth driven by the June 2025 acquisition of Pivot Onsite Innovations, adding over 240 onsite locations
Biggest Revenue Drivers
Total revenue: $606.0M+10.0% YoY
Occupational health centers$553.5M
91% of revenue; driven by organic increases in patient visit volume and revenue per visit
Within Occupational health centers
Workers' compensation$361.2M
Higher reimbursement rates under state fee schedules; revenue per visit up 4.9% to $219.06
Employer services$183.2M
Revenue per visit up 3.2% to $95.84 on rate increases
Onsite health clinics$38.8Mvs $22.6M prior year
Growth driven by the June 2025 acquisition of Pivot Onsite Innovations, adding over 240 onsite locations
Other businesses$13.7M
Includes Concentra Telemed, Concentra Pharmacy, and Concentra Medical Compliance Administration
Largest Expense Items
Cost of services$413.9M68.3% of revenue vs 70.7% prior year
Decreased as % of revenue due to increased staffing efficiencies and elimination of one-time Nova expenses via synergies
General and administrative$56.7M9.4% of revenue vs 9.6% prior year
One-time Nova and Pivot expenses in 2025 offset by new hires, stock compensation, and standalone public company costs
Depreciation and amortization$19.9M
Increase primarily due to recent growth through de novos and acquisitions
Interest expense$25.7Mdown from $28.2M
Decrease due to term loan amortization and repayment of $85M Revolving Credit Facility borrowings
Margins: Income from operations margin expanded to 19.0% from 16.3% YoY, driven by cost of services falling to 68.3% of revenue from 70.7% on staffing efficiencies and the elimination of one-time Nova acquisition costs incurred in the prior-year quarter.
Watch Items from the Filing
A qui tam lawsuit unsealed November 10, 2025 alleges the Company's physical therapy referral guidelines led to false claims submitted to insurers, following a related California Department of Insurance subpoena from February 2024.
A DOJ False Claims Act investigation into physical therapy billing (originally targeting former parent Select) continues, with a related qui tam suit unsealed in May 2024; Concentra is not a named defendant but is cooperating.
The PJ&A third-party vendor data breach affected almost four million patients; six consolidated class actions remain pending, though the Company does not expect a material financial impact.
Leverage ratio was 2.99x versus a covenant maximum of 6.5x, and $430.2M remained available under the Revolving Credit Facility, indicating substantial balance sheet flexibility.
Occupational health centers remained 91% of revenue (down from 94% a year ago) as onsite health clinics grew to 7% following the Pivot acquisition, showing gradual diversification.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
